Diabetes Obes Metab:持续血糖控制不良与心血管事件发生相关

2016-01-25 phylis 译 MedSci原创

目的:CREDIT(胰岛素治疗的2型糖尿病的心血管风险评估)是一种非干预性研究,旨在探讨欧洲,北美和亚洲地区,临床上开始规律使用胰岛素的患者糖化血红蛋白(HbA1c)和心血管(CV)事件之间的关系。材料与方法:从医生报告中前瞻性收集了4年的数据,共2999人。主要预后是中风或心肌梗死或心血管疾病死亡的复合。应用Cox比例风险模型描述心血管事件的相对危险,将不变更新的平均HbA1c值作为时间依赖性协

目的:CREDIT(胰岛素治疗的2型糖尿病的心血管风险评估)是一种非干预性研究,旨在探讨欧洲、北美和亚洲地区,临床上开始规律使用胰岛素的患者的糖化血红蛋白(HbA1c)和心血管(CV)事件之间的关系。

材料与方法:从前瞻性收集了4年的医生报告的数据,共2999人。主要预后是中风或心肌梗死或心血管疾病死亡的复合。应用Cox比例风险模型描述心血管事件的相对危险,将不断更新的平均HbA1c值作为时间依赖性协变量。研究有CV的严重或症状性低血糖(在年度认定前6个月收集)和全因死亡的关系。

结果:在长达54个月的随访期,共发生147件主要预后事件。60例心血管死亡事件,44例非致命性心肌梗死事件,57件非致命性卒中事件,共计161件。更新的平均HbA1c和主要预后呈正相关(HR: 1.25 95%CI:  1.12-1.40)。心血管死亡(1.31 [ 1.10-1.57 ])和卒中(1.36 [ 1.17-1.59 ])均与糖化血红蛋白密切相关;MI(1.05 [ 0.83-1.32 ])与糖化血红蛋白不相关。175人发生一次或多次严重低血糖,而1508人经历了一次或多次症状性低血糖的发生。研究者发现严重/症状性低血糖事件与CV/各种原因死亡之间没有相关性。

结论:持续血糖控制不佳与心血管事件发生有关;低血糖与CV/各种原因死亡不相关。

原文出处:

Freemantle N, Danchin N, et al. Relationship of glycaemic control and hypoglycaemic episodes to 4-year CV outcomes in people with type 2 diabetes starting insulin. Diabetes Obes Metab. 2015 Oct 29.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (19)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1637266, encodeId=429c163e26635, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Sep 15 14:46:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887506, encodeId=fcb7188e506ce, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 18:46:00 CST 2016, time=2016-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895881, encodeId=1f6e189588164, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 09 18:46:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759633, encodeId=180b1e5963363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 01 05:46:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901348, encodeId=4d3919013484c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 02 05:46:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68569, encodeId=57e86856977, content=希望有更大样本相关研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a411691127, createdName=1de5aaa9m95(暂无匿称), createdTime=Fri Mar 11 08:35:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643395, encodeId=a6e2164339576, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 10 22:46:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62330, encodeId=1f7262330f8, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Jan 31 12:42:00 CST 2016, time=2016-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61918, encodeId=08d2619182f, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Fri Jan 29 00:19:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61403, encodeId=46e56140390, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 23:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1637266, encodeId=429c163e26635, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Sep 15 14:46:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887506, encodeId=fcb7188e506ce, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 18:46:00 CST 2016, time=2016-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895881, encodeId=1f6e189588164, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 09 18:46:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759633, encodeId=180b1e5963363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 01 05:46:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901348, encodeId=4d3919013484c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 02 05:46:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68569, encodeId=57e86856977, content=希望有更大样本相关研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a411691127, createdName=1de5aaa9m95(暂无匿称), createdTime=Fri Mar 11 08:35:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643395, encodeId=a6e2164339576, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 10 22:46:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62330, encodeId=1f7262330f8, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Jan 31 12:42:00 CST 2016, time=2016-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61918, encodeId=08d2619182f, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Fri Jan 29 00:19:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61403, encodeId=46e56140390, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 23:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-08-08 guojianrong
  3. [GetPortalCommentsPageByObjectIdResponse(id=1637266, encodeId=429c163e26635, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Sep 15 14:46:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887506, encodeId=fcb7188e506ce, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 18:46:00 CST 2016, time=2016-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895881, encodeId=1f6e189588164, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 09 18:46:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759633, encodeId=180b1e5963363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 01 05:46:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901348, encodeId=4d3919013484c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 02 05:46:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68569, encodeId=57e86856977, content=希望有更大样本相关研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a411691127, createdName=1de5aaa9m95(暂无匿称), createdTime=Fri Mar 11 08:35:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643395, encodeId=a6e2164339576, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 10 22:46:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62330, encodeId=1f7262330f8, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Jan 31 12:42:00 CST 2016, time=2016-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61918, encodeId=08d2619182f, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Fri Jan 29 00:19:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61403, encodeId=46e56140390, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 23:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-05-09 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1637266, encodeId=429c163e26635, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Sep 15 14:46:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887506, encodeId=fcb7188e506ce, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 18:46:00 CST 2016, time=2016-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895881, encodeId=1f6e189588164, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 09 18:46:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759633, encodeId=180b1e5963363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 01 05:46:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901348, encodeId=4d3919013484c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 02 05:46:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68569, encodeId=57e86856977, content=希望有更大样本相关研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a411691127, createdName=1de5aaa9m95(暂无匿称), createdTime=Fri Mar 11 08:35:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643395, encodeId=a6e2164339576, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 10 22:46:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62330, encodeId=1f7262330f8, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Jan 31 12:42:00 CST 2016, time=2016-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61918, encodeId=08d2619182f, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Fri Jan 29 00:19:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61403, encodeId=46e56140390, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 23:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1637266, encodeId=429c163e26635, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Sep 15 14:46:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887506, encodeId=fcb7188e506ce, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 18:46:00 CST 2016, time=2016-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895881, encodeId=1f6e189588164, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 09 18:46:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759633, encodeId=180b1e5963363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 01 05:46:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901348, encodeId=4d3919013484c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 02 05:46:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68569, encodeId=57e86856977, content=希望有更大样本相关研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a411691127, createdName=1de5aaa9m95(暂无匿称), createdTime=Fri Mar 11 08:35:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643395, encodeId=a6e2164339576, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 10 22:46:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62330, encodeId=1f7262330f8, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Jan 31 12:42:00 CST 2016, time=2016-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61918, encodeId=08d2619182f, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Fri Jan 29 00:19:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61403, encodeId=46e56140390, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 23:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1637266, encodeId=429c163e26635, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Sep 15 14:46:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887506, encodeId=fcb7188e506ce, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 18:46:00 CST 2016, time=2016-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895881, encodeId=1f6e189588164, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 09 18:46:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759633, encodeId=180b1e5963363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 01 05:46:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901348, encodeId=4d3919013484c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 02 05:46:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68569, encodeId=57e86856977, content=希望有更大样本相关研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a411691127, createdName=1de5aaa9m95(暂无匿称), createdTime=Fri Mar 11 08:35:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643395, encodeId=a6e2164339576, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 10 22:46:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62330, encodeId=1f7262330f8, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Jan 31 12:42:00 CST 2016, time=2016-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61918, encodeId=08d2619182f, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Fri Jan 29 00:19:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61403, encodeId=46e56140390, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 23:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-03-11 1de5aaa9m95(暂无匿称)

    希望有更大样本相关研究

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1637266, encodeId=429c163e26635, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Sep 15 14:46:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887506, encodeId=fcb7188e506ce, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 18:46:00 CST 2016, time=2016-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895881, encodeId=1f6e189588164, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 09 18:46:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759633, encodeId=180b1e5963363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 01 05:46:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901348, encodeId=4d3919013484c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 02 05:46:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68569, encodeId=57e86856977, content=希望有更大样本相关研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a411691127, createdName=1de5aaa9m95(暂无匿称), createdTime=Fri Mar 11 08:35:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643395, encodeId=a6e2164339576, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 10 22:46:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62330, encodeId=1f7262330f8, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Jan 31 12:42:00 CST 2016, time=2016-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61918, encodeId=08d2619182f, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Fri Jan 29 00:19:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61403, encodeId=46e56140390, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 23:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1637266, encodeId=429c163e26635, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Sep 15 14:46:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887506, encodeId=fcb7188e506ce, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 18:46:00 CST 2016, time=2016-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895881, encodeId=1f6e189588164, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 09 18:46:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759633, encodeId=180b1e5963363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 01 05:46:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901348, encodeId=4d3919013484c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 02 05:46:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68569, encodeId=57e86856977, content=希望有更大样本相关研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a411691127, createdName=1de5aaa9m95(暂无匿称), createdTime=Fri Mar 11 08:35:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643395, encodeId=a6e2164339576, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 10 22:46:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62330, encodeId=1f7262330f8, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Jan 31 12:42:00 CST 2016, time=2016-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61918, encodeId=08d2619182f, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Fri Jan 29 00:19:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61403, encodeId=46e56140390, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 23:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-31 忠诚向上

    好好学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1637266, encodeId=429c163e26635, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Sep 15 14:46:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887506, encodeId=fcb7188e506ce, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 18:46:00 CST 2016, time=2016-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895881, encodeId=1f6e189588164, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 09 18:46:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759633, encodeId=180b1e5963363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 01 05:46:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901348, encodeId=4d3919013484c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 02 05:46:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68569, encodeId=57e86856977, content=希望有更大样本相关研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a411691127, createdName=1de5aaa9m95(暂无匿称), createdTime=Fri Mar 11 08:35:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643395, encodeId=a6e2164339576, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 10 22:46:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62330, encodeId=1f7262330f8, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Jan 31 12:42:00 CST 2016, time=2016-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61918, encodeId=08d2619182f, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Fri Jan 29 00:19:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61403, encodeId=46e56140390, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 23:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-29 circlegirl

    文章不错

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1637266, encodeId=429c163e26635, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Sep 15 14:46:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887506, encodeId=fcb7188e506ce, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 18:46:00 CST 2016, time=2016-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895881, encodeId=1f6e189588164, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 09 18:46:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759633, encodeId=180b1e5963363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 01 05:46:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901348, encodeId=4d3919013484c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 02 05:46:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68569, encodeId=57e86856977, content=希望有更大样本相关研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a411691127, createdName=1de5aaa9m95(暂无匿称), createdTime=Fri Mar 11 08:35:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643395, encodeId=a6e2164339576, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 10 22:46:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62330, encodeId=1f7262330f8, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Jan 31 12:42:00 CST 2016, time=2016-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61918, encodeId=08d2619182f, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Fri Jan 29 00:19:00 CST 2016, time=2016-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61403, encodeId=46e56140390, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 23:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 doctording1

    值得进一步关注

    0

相关资讯

Lancet Diabetes Endocrinol:中国早发糖尿病患者发生非致命的心血管疾病的风险增加

背景:2型糖尿病发病年龄降低。因为早发2型糖尿病非中国患者(这里定义为40岁以下的患者),血管并发症的风险增加,研究者调查了中国早发性和迟发性2型糖尿病对非致命的心血管疾病发生风险的影响。方法:研究者使用中国糖化血红蛋白监测系统数据调查(CNHSS)的数据进行横断面的调查研究,包括2012年中国30省106个城市630家医院2型糖尿病患者222 773名。研究者记录了人口学资料和临床资料。非致命性

PLoS One:雌激素可能降低老年女性糖尿病患者发生缺血性卒中的风险

本研究旨在探讨缺血性卒中风险和55岁以上糖尿病女性患者结合雌激素(CEE)使用之间可能存在的联系。从台湾国家健康保险系统中收集2003到2009年间,使用CEE 55岁以上糖尿病女性患者(每天0.625毫克)428例。为了进行比较,21026名来自同一个队列没有使用雌激素的糖尿病女性患者作为对照组,排除存在缺血性卒中史的患者。应用倾向评分方法按照1:3的比例确定为对照组(n = 1284)。倾向评

Atherosclerosis:阿利吉仑对糖尿病患者和非糖尿病患者的影响(AQUQRIUS)

背景:以前发现阿利吉仑在规定应用血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体拮抗剂(ARB)糖尿病患者中存在潜在的有害影响。研究者探讨了阿利吉仑对糖尿病患者和非糖尿病患者冠状动脉粥样硬化的进展和主要不良心血管事件(MACE:死亡、非致死性心肌梗死、非致死性卒中或因心力衰竭住院、因ACS住院、动脉血运重建)的影响。方法:AQUQRIUS研究对冠脉疾病患者进行血管内超声检测冠状动脉硬化斑块的体积

BMJ Open:刷牙也能影响身体健康,每天刷几次合适?

该研究的目的是明确刷牙和心血管疾病,高血压(HT),糖尿病(DM),血脂异常(DL),高尿酸血症(HUA)和慢性肾脏病(CKD)风险因素之间的关系。该大型,单中心,横断面研究在2004年1月和2010年6月之间日本东京的圣路加国际医院,预防医学中心进行。本研究根据3类刷牙频率标准对85866人刷牙习惯进行了检测:“至少每天一次”和“不到一天一次”“每顿饭后”。根据频率得出的ORs计算了HT,DM,

J Hypertens:糖尿病的卒中患者,抗高血压: ACEI or ARB ?

目的:肾素-血管紧张素-醛固酮系统阻滞剂是糖尿病和卒中患者首选的抗高血压药物。本研究旨在比较血管紧张素转换酶抑制剂(ACEI)及血管紧张素II受体阻滞剂(ARBs)对卒中幸存者存在糖尿病的患者不良心血管事件(MACE)的影响。方法:研究者使用台湾的国家健康保险研究数据库进行了一项观察性研究,全国范围内,倾向得分匹配队列研究。将20岁以上的2型糖尿病患者,2000年1月和2011年12月期间首发缺血

Am J Gastroenterol:急性胰腺炎使糖尿病风险增加两倍

研究者进行了一项研究,使用基于人群的研究评估急性胰腺炎(AP)后糖尿病发生风险。该研究纳入了2966名第一次患AP的患者和11864名非AP对照组,在性别和年龄上与AP组匹配。泊松假设下估计糖尿病发病率。使用Cox比例风险回归模型计算相关HRs。研究数据显示,<3个月的时间内,AP组和对照组糖尿病发生率分别为 60.8/1000人年和8.0/1000人年,多因素校正后HR=5.90 (95% CI